Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone use in patients with chronic fatty liver disease and newly diagnosed type 2 diabetes mellitus
2007-007884-26Phase 4Completed
- Sponsor
- HUS, HYKS, Diabetesklinikka
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pioglitazone in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM), sponsored by HUS, HYKS, Diabetesklinikka. Primary endpoint: Change in hepatic fat content. Started Jan 2008; status: completed.
02
Drugs
pioglitazone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-007884-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007884-26.